Lejla Alidzanovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lejla Alidzanovic has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Almedina Muhic
Department of Oncology and Radiotherapy, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
1 shared publication - Amila Kovcic
Clinic for Oncology and Radiotherapy, University Clinical Center Tuzla, 75000 Tuzla, Bosnia and Herzegovina
1 shared publication - Anida Sehic
Clinic for Oncology and Radiotherapy, University Clinical Center Tuzla, 75000 Tuzla, Bosnia and Herzegovina
1 shared publication - Lora Novaković-Lacković
Univerzitetski klinički centar Republike Srpske, Klinika za plućne bolesti, Banja Luka, Republika Srpska
1 shared publication - Medina Bandovic Kuduzovic
Clinic for Pulmology, University Clinical Center Tuzla, 75000 Tuzla, Bosnia and Herzegovina
1 shared publication - Nejra Selak
Department of Pathology, Faculty of Medicine, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina
1 shared publication
Latest Publications
- Open Access
- 25 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2219
Prognostic Value of Systemic Immune Inflammation Index in Squamous Cell Lung Cancer
Background/Objectives: Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. Methods: This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Results: Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all p < 0.05). Conclusions: These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.
- 25 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2219
Open AccessPrognostic Value of Systemic Immune Inflammation Index in Squamous Cell Lung Cancer
Background/Objectives: Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. Methods: This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Results: Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all p < 0.05). Conclusions: These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.